Celgene Gets CHMP Positive Opinions for Revlimid, Imnovid Combos in Multiple Myeloma
March 29 2019 - 9:09AM
Dow Jones News
By Colin Kellaher
Celgene Corp. (CELG) on Friday said the European Medicines
Agency's Committee for Medicinal Products for Human Use adopted
positive opinions for a pair of triplet regimens based on its
Revlimid and Imnovid medications in multiple myeloma.
The Summit, N.J., biopharmaceutical company said the panel
recommended European Commission approval of Revlimid in combination
with bortezomib and dexamethasone in adults with previously
untreated multiple myeloma who aren't eligible for transplant.
Celgene, which in January announced a deal to be acquired by
Bristol-Myers Squibb Co. (BMY), said the CHMP also recommended
approval of Imnovid in combination with bortezomib and
dexamethasone for adults with multiple myeloma who have received at
least one prior treatment regimen including lenalidomide.
Multiple myeloma is a cancer that forms in a type of white blood
cells called plasma cells and causes cancer cells to accumulate in
the bone marrow.
Celgene said the European Commission, which generally follows
the CHMP's recommendations, is expected to make its final decision
in about two months.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 29, 2019 08:54 ET (12:54 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Jul 2023 to Jul 2024